Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach

Autor: Kramer RM, Archer MC, Orr MT, Dubois Cauwelaert N, Beebe EA, Huang PWD, Dowling QM, Schwartz AM, Fedor DM, Vedvick TS, Fox CB

Publikováno v: International Journal of Nanomedicine, Vol Volume 13, Pp 3689-3711 (2018)

Ryan M Kramer, Michelle C Archer, Mark T Orr, Natasha Dubois Cauwelaert, Elyse A Beebe, Po-wei D Huang, Quinton M Dowling, Alicia M Schwartz, Dawn M Fedor, Thomas S Vedvick, Christopher B Fox Infectious Disease Research Institute, Seattle, WA, USA Ba

Externí odkaz: https://doaj.org/article/77071a8c5e9b459690ee594b3567806d

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.

Autor: Fox CB; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA; Dept of Global Health, University of Washington, Seattle, WA 98104, USA. Electronic address: cfox@idri.org., Orr MT; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA; Dept of Global Health, University of Washington, Seattle, WA 98104, USA., Van Hoeven N; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA., Parker SC; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA., Mikasa TJ; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA., Phan T; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA., Beebe EA; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA., Nana GI; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA., Joshi SW; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA., Tomai MA; 3M Drug Delivery Systems, 3M Center, 275-3E-10, St. Paul, MN 55144, USA., Elvecrog J; 3M Drug Delivery Systems, 3M Center, 275-3E-10, St. Paul, MN 55144, USA., Fouts TR; Profectus Biosciences, Inc., Baltimore, MD 21224, USA., Reed SG; IDRI, 1616 Eastlake Ave, Seattle, WA 98102, USA; Dept of Global Health, University of Washington, Seattle, WA 98104, USA.

Publikováno v: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2016 Dec 28; Vol. 244 (Pt A), pp. 98-107. Date of Electronic Publication: 2016 Nov 12.

Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.

Autor: Orr MT; Infectious Disease Research Institute, Seattle, WA 98102, USA; Department of Global Health, University of Washington, Seattle, WA 98105, USA. Electronic address: Mark.orr@idri.org., Beebe EA; Infectious Disease Research Institute, Seattle, WA 98102, USA., Hudson TE; Infectious Disease Research Institute, Seattle, WA 98102, USA., Argilla D; Infectious Disease Research Institute, Seattle, WA 98102, USA., Huang PW; Infectious Disease Research Institute, Seattle, WA 98102, USA., Reese VA; Infectious Disease Research Institute, Seattle, WA 98102, USA., Fox CB; Infectious Disease Research Institute, Seattle, WA 98102, USA; Department of Global Health, University of Washington, Seattle, WA 98105, USA., Reed SG; Infectious Disease Research Institute, Seattle, WA 98102, USA; Department of Global Health, University of Washington, Seattle, WA 98105, USA., Coler RN; Infectious Disease Research Institute, Seattle, WA 98102, USA; Department of Global Health, University of Washington, Seattle, WA 98105, USA.

Publikováno v: Vaccine [Vaccine] 2015 Nov 27; Vol. 33 (48), pp. 6570-8. Date of Electronic Publication: 2015 Nov 03.

Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.

Autor: Orr MT; Infectious Disease Research Institute Department of Global Health, University of Washington, Seattle., Windish HP; Infectious Disease Research Institute., Beebe EA; Infectious Disease Research Institute., Argilla D; Infectious Disease Research Institute., Huang PW; Infectious Disease Research Institute., Reese VA; Infectious Disease Research Institute., Reed SG; Infectious Disease Research Institute Department of Global Health, University of Washington, Seattle., Coler RN; Infectious Disease Research Institute Department of Global Health, University of Washington, Seattle.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2015 Aug 01; Vol. 212 (3), pp. 495-504. Date of Electronic Publication: 2015 Jan 30.

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Autor: Orr MT; Infectious Disease Research Institute, Seattle, WA 98102, USA. Electronic address: mark.orr@idri.org., Kramer RM; Infectious Disease Research Institute, Seattle, WA 98102, USA., Barnes L 5th; Infectious Disease Research Institute, Seattle, WA 98102, USA., Dowling QM; Infectious Disease Research Institute, Seattle, WA 98102, USA., Desbien AL; Infectious Disease Research Institute, Seattle, WA 98102, USA., Beebe EA; Infectious Disease Research Institute, Seattle, WA 98102, USA., Laurance JD; Infectious Disease Research Institute, Seattle, WA 98102, USA., Fox CB; Infectious Disease Research Institute, Seattle, WA 98102, USA., Reed SG; Infectious Disease Research Institute, Seattle, WA 98102, USA., Coler RN; Infectious Disease Research Institute, Seattle, WA 98102, USA., Vedvick TS; Infectious Disease Research Institute, Seattle, WA 98102, USA.

Publikováno v: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2014 Mar 10; Vol. 177, pp. 20-6. Date of Electronic Publication: 2013 Dec 29.